SCHEMBL946635

SCHEMBL946635

CC(C)(O)c1ccccn1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.67
L3MBTL1 Q9Y468 1/20 0.67
AHR P35869 2/20 0.45
CHRM2 P08172 1/20 0.41
BLM P54132 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
POLB P06746 1/20 0.40
CCR1 P32246 1/20 0.40
CCR5 P51681 1/20 0.40
CCR8 P51685 1/20 0.40
METAP1 P53582 1/20 0.40
HIF1A Q16665 1/20 0.40
DOHH Q9BU89 1/20 0.40
P4HTM Q9NXG6 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CHRM3 P20309 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29965849 1.00 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL6921056 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL12717303 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL4388586 0.86 SMN1; SMN2 (0.67) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL27997203 0.84 SMN1; SMN2 (0.64) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL10442032 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL21742008 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL16230664 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL17490343 0.81 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1AHRCHRM2BLM
SCHEMBL21883522 0.81 L3MBTL1 (0.55) SMN1; SMN2L3MBTL1AHRCHRM2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 214 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240189805-A1 CATALYSTS AND METHODS FOR THE HYDRATION AND ABSORPTION OF CARBON DIOXIDE AIR COMPANY HOLDINGS, INC. 2024-06-13 US claimed
EP-4341235-A1 METHOD AND APPARATUS FOR SELECTIVE ALCOHOL UPGRADING Air Company Holdings, Inc. (US) 2024-03-27 EP claimed
EP-4313373-A1 CATALYSTS AND METHODS FOR THE HYDRATION AND ABSORPTION OF CARBON DIOXIDE Air Company Holdings, Inc. (US) 2024-02-07 EP claimed
WO-2022245944-A1 METHOD AND APPARATUS FOR SELECTIVE ALCOHOL UPGRADING AIR COMPANY HOLDINGS, INC. (US) 2022-11-24 WO claimed
WO-2022204233-A1 CATALYSTS AND METHODS FOR THE HYDRATION AND ABSORPTION OF CARBON DIOXIDE AIR COMPANY HOLDINGS, INC. (US) 2022-09-29 WO claimed
CN-109153665-A Novel 2-substituted indazoles, method for the production thereof, pharmaceutical preparations containing the same and use thereof for producing medicaments 拜耳医药股份有限公司 2019-01-04 CN claimed
US-9790605-B2 Iridium complexes for electrocatalysis YALE UNIVERSITY (US) 2017-10-17 US claimed
CN-106795139-A Aminopyridine base epoxide pyrazole compound 伊莱利利公司 2017-05-31 CN claimed
US-20150021194-A1 IRIDIUM COMPLEXES FOR ELECTROCATALYSIS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-01-22 US claimed
US-12448383-B2 Compounds and methods for treatment of viral infections GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 US disclosed
US-20250197410-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS GILEAD SCIENCES, INC. 2025-06-19 US disclosed
US-20250178992-A1 METHOD AND APPARATUS FOR SELECTIVE ALCOHOL UPGRADING AIR COMPANY HOLDINGS, INC. 2025-06-05 US disclosed
US-12252462-B2 Method and apparatus for selective alcohol upgrading AIR COMPANY HOLDINGS, INC. (US) 2025-03-18 US disclosed
EP-1036081-A1 HETEROCYCLYL LIGAND CONTAINING RUTHENIUM AND OSMIUM CATALYSTS Ciba SC Holding AG (CH) 2000-09-20 EP disclosed
US-5969166-A RUTHENIUM OR MOLYBDENUM CATALYSTS FOR EPOXIDATION OF ALKENES WITH OXYGEN HOECHST AKTIENGESELLSCHAFT (DE) 1999-10-19 US disclosed
WO-1999029701-A1 HETEROCYCLYL LIGAND CONTAINING RUTHENIUM AND OSMIUM CATALYSTS CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) 1999-06-17 WO disclosed
US-5256785-A Smoking compositions containing an oxalate flavorant-release additive PHILIP MORRIS INCORPORATED (US) 1993-10-26 US disclosed
US-5172706-A Smoking compositions containing an oxalate flavorant-release additive PHILIP MORRIS INCORPORATED (US) 1992-12-22 US disclosed
US-4546198-A Asymmetric synthesis of esters and acids SHELL OIL COMPANY (US) 1985-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250178992-A1 METHOD AND APPARATUS FOR SELECTIVE ALCOHOL UPGRADING ADH1C, ADH1A, ADH5 SMN1; SMN2 2967/4885L3MBTL1 3769/4885AHR 136/4885
US-12252462-B2 Method and apparatus for selective alcohol upgrading ADH1C, ADH1A, ADH5 SMN1; SMN2 2967/4885L3MBTL1 3769/4885AHR 136/4885
US-20250304577-A1 TYK2 INHIBITORS TYK2, JAK2, JAK1 SMN1; SMN2 1067/4885L3MBTL1 2886/4885AHR 2943/4885
US-20150021194-A1 IRIDIUM COMPLEXES FOR ELECTROCATALYSIS PPOX, NOXO1, NOX3 SMN1; SMN2 2055/4885L3MBTL1 3177/4885AHR 2388/4885
US-12448383-B2 Compounds and methods for treatment of viral infections HAVCR2, EIF2AK2, OAT SMN1; SMN2 1064/4885L3MBTL1 2363/4885AHR 3343/4885
US-20250197410-A1 COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS HAVCR2, EIF2AK2, OAT SMN1; SMN2 1064/4885L3MBTL1 2363/4885AHR 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.